{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T23:08:20Z","timestamp":1779404900205,"version":"3.53.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurodevelopmental disorders (NDDs) are genetically heterogeneous, and standard genomic testing frequently yields variants of uncertain significance (VUS) or misses cryptic structural variants. Episignature analysis, which detects disorder specific genome-wide DNA methylation patterns, has emerged as a functional tool to resolve diagnostic uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a 7-year-old female with global developmental delay, autism spectrum disorder, epilepsy, microcephaly, and a distinctive facial gestalt. Initial trio whole-exome sequencing identified inconclusive VUSs in\n                      <jats:italic>CAD<\/jats:italic>\n                      and\n                      <jats:italic>POLR1A<\/jats:italic>\n                      . A therapeutic trial of uridine for the\n                      <jats:italic>CAD<\/jats:italic>\n                      -related variants provided only transient benefit. Genome-wide DNA methylation analysis via EpiSign revealed a positive result for the episignature for Intellectual Developmental Disorder, Autosomal Dominant 7 (MRD7), associated with DYRK1A haploinsufficiency. Guided by this result, trio whole-genome sequencing identified a\n                      <jats:italic>de novo<\/jats:italic>\n                      heterozygous deletion involving exon 5 of\n                      <jats:italic>DYRK1A<\/jats:italic>\n                      . The exact breakpoints were chr21:38,852,074\u201338,856,009 (GRCh37\/hg19) and chr21:39,044,532\u201339,048,467 (GRCh38\/hg38). This variant was reclassified from VUS to likely pathogenic based on concordant episignatures findings, clinical phenotype, and\n                      <jats:italic>de novo<\/jats:italic>\n                      occurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the utility of episignature analysis to help diagnose NDD patients, guide further molecular diagnostic testing, and as a functional assay to aid variant reclassification. Integration of epigenomic profiling with standard of care testing can shorten the diagnostic odyssey, prevent unnecessary interventions, and directly inform clinical management in patients with unresolved NDDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1813300","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:10:16Z","timestamp":1779401416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Episignature leads to diagnosis and reclassification of DYRK1A variant in a child with syndromic neurodevelopmental disorder: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Inas","family":"Al-Younis","sequence":"first","affiliation":[{"name":"Vitalit\u00e9 Health Network, Dr Georges-L.-Dumont University Hospital Center","place":["Moncton, NB, Canada"]},{"name":"Department of Chemistry and Biochemistry, New Brunswick Centre for Precision Medicine, Universit\u00e9 de Moncton","place":["Moncton, NB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Basque","sequence":"additional","affiliation":[{"name":"Centre de Formation M\u00e9dicale du Nouveau Brunswick, Moncton","place":["NB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Crapoulet","sequence":"additional","affiliation":[{"name":"Vitalit\u00e9 Health Network, Dr Georges-L.-Dumont University Hospital Center","place":["Moncton, NB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dyack","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Dalhousie University","place":["Halifax, NS, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"del Ca\u00f1o-Ochoa","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina de Valencia (IBV), Consejo Superior de Investigaciones Cient\u00edficas (CSIC)","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ram\u00f3n-Maiques","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina de Valencia (IBV), Consejo Superior de Investigaciones Cient\u00edficas (CSIC)","place":["Valencia, Spain"]},{"name":"Centro de Investigacion Biom\u00e9dica en Red de Enfermedades Raras (CIBERER)\u2013Instituto de Salud Carlos III","place":["Valencia, Spain"]},{"name":"Valencia Biomedical Research Foundation, Centro de Investigaci\u00f3n Pr\u00edncipe Felipe (CIPF) - Associated Unit to the Instituto de Biomedicina de Valencia (IBV)","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara B.","family":"MacKay","sequence":"additional","affiliation":[{"name":"Maritime Medical Genetics Service, Izaak Walton Killam (IWK) Health Centre","place":["Halifax, NS, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rzasa","sequence":"additional","affiliation":[{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre","place":["London, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekim","family":"Sadikovic","sequence":"additional","affiliation":[{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre","place":["London, ON, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University","place":["London, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"McConkey","sequence":"additional","affiliation":[{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre","place":["London, ON, Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University","place":["London, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ben Amor","sequence":"additional","affiliation":[{"name":"Vitalit\u00e9 Health Network, Dr Georges-L.-Dumont University Hospital Center","place":["Moncton, NB, Canada"]},{"name":"Centre de Formation M\u00e9dicale du Nouveau Brunswick, Moncton","place":["NB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/15592294.2017.1381807","article-title":"The defining DNA methylation signature of kabuki syndrome enables functional assessment of genetic variants of unknown clinical significance","volume":"12","author":"Aref-Eshghi","year":"2017","journal-title":"Epigenetics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1038\/s41467-018-07193-y","article-title":"BAFopathies\u2019 DNA methylation epi-signatures demonstrate diagnostic utility and functional continuum of coffin-siris and nicolaides-baraitser syndromes","volume":"9","author":"Aref-Eshghi","year":"","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajhg.2017.12.008","article-title":"Genomic DNA methylation signatures enable concurrent diagnosis and clinical genetic variant classification in neurodevelopmental syndromes","volume":"102","author":"Aref-Eshghi","year":"","journal-title":"Am. J. Hum. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ajhg.2019.03.008","article-title":"Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions","volume":"104","author":"Aref-Eshghi","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ajhg.2020.01.019","article-title":"Evaluation of DNA methylation episignatures for diagnosis and phenotype correlations in 42 mendelian neurodevelopmental disorders","volume":"106","author":"Aref-Eshghi","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"B6","unstructured":"DYRK1A syndrome\n          \n          \n          2015"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/ejhg.2015.29","article-title":"Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A","volume":"23","author":"Bronicki","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41436-020-0898-y","article-title":"De novo SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from Nicolaides-Baraitser syndrome","volume":"22","author":"Cappuccio","year":"2020","journal-title":"Genet. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100896","DOI":"10.1016\/j.gim.2023.100896","article-title":"Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations","volume":"25","author":"Chung","year":"2023","journal-title":"Genet. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41525-018-0053-8","article-title":"Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases","volume":"3","author":"Clark","year":"2018","journal-title":"NPJ Genom Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41436-021-01263-1","article-title":"Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder","volume":"23","author":"Courraud","year":"2021","journal-title":"Genet. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/mp.2016.253","article-title":"Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development","volume":"23","author":"Dang","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1206524","article-title":"Diagnostic exome sequencing in persons with severe intellectual disability","volume":"367","author":"de Ligt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41436-020-0833-2","article-title":"Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy","volume":"22","author":"Del Ca\u00f1o-Ochoa","year":"2020","journal-title":"Genet. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jimd.12667","article-title":"Beyond genetics: deciphering the impact of missense variants in CAD deficiency","volume":"46","author":"Del Ca\u00f1o-Ochoa","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8100187","article-title":"DYRK1A protein, A promising therapeutic target to improve cognitive deficits in Down syndrome","volume":"8","author":"Feki","year":"2018","journal-title":"Brain Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","article-title":"The diverse roles of DNA methylation in mammalian development and disease","volume":"20","author":"Greenberg","year":"2019","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ajhg.2024.07.005","article-title":"Identification of a DNA methylation episignature for recurrent constellations of embryonic malformations","volume":"111","author":"Haghshenas","year":"","journal-title":"Am. J. Hum. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"101226","DOI":"10.1016\/j.gim.2024.101226","article-title":"Discovery of DNA methylation signature in the peripheral blood of individuals with history of antenatal exposure to valproic acid","volume":"26","author":"Haghshenas","year":"","journal-title":"Genet. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/ejhg.2015.71","article-title":"DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies","volume":"23","author":"Ji","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1755-8794-6-58","article-title":"Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in Down syndrome","volume":"6","author":"Jones","year":"2013","journal-title":"BMC Med. Genomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101075","DOI":"10.1016\/j.gim.2024.101075","article-title":"Diagnostic utility and reporting recommendations for clinical DNA methylation episignature testing in genetically undiagnosed rare diseases","volume":"26","author":"Kerkhof","year":"2024","journal-title":"Genet. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1528-1167.2012.03516.x","article-title":"Targeted next generation sequencing as a diagnostic tool in epileptic disorders","volume":"53","author":"Lemke","year":"2012","journal-title":"Epilepsia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.xhgg.2021.100075","article-title":"Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders","volume":"3","author":"Levy","year":"2022","journal-title":"HGG Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e63864","DOI":"10.1002\/ajmg.a.63864","article-title":"Diagnosis of TET3-Related beck-fahrner syndrome in an individual with chorioretinal and iris colobomata using a DNA methylation signature","volume":"197","author":"Man","year":"2025","journal-title":"Am. J. Med. Genet. A"},{"key":"B26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.chc.2017.03.001","article-title":"Intellectual disability and language disorder","volume":"26","author":"Marrus","year":"2017","journal-title":"Child. Adolesc. Psychiatr. Clin. N. Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s10038-023-01203-8","article-title":"Integrated omics analyses clarifies ATRX copy number variant of uncertain significance","volume":"69","author":"Marshall","year":"2024","journal-title":"J. Hum. Genet."},{"key":"B28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/B978-0-443-21863-7.00012-3","article-title":"Epigenomic mechanisms and episignature biomarkers in rare diseases","volume-title":"Epigenetics in human disease","author":"McConkey","year":"2024"},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1391564","DOI":"10.3389\/fnmol.2024.1391564","article-title":"Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions","volume":"17","author":"Murphy","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e33379","DOI":"10.7759\/cureus.33379","article-title":"Whole-exome sequencing identified a novel DYRK1A variant in a patient with intellectual developmental disorder, autosomal dominant 7","volume":"15","author":"Obara","year":"2023","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/children4050042","article-title":"Genetic testing among children in a complex care program","volume":"4","author":"Oei","year":"2017","journal-title":"Child. (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101398","DOI":"10.1016\/j.gim.2025.101398","article-title":"A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseases","volume":"27","author":"Pandey","year":"2025","journal-title":"Genet. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fnins.2021.776809","article-title":"The epigenome in neurodevelopmental disorders","volume":"15","author":"Reichard","year":"2021","journal-title":"Front. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41436-020-01096-4","article-title":"Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders","volume":"23","author":"Sadikovic","year":"2021","journal-title":"Genet. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13148-018-0453-8","article-title":"Peripheral blood epi-signature of claes-jensen syndrome enables sensitive and specific identification of patients and healthy carriers with pathogenic mutations in KDM5C","volume":"10","author":"Schenkel","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/humu.22332","article-title":"Targeted next-generation sequencing can replace sanger sequencing in clinical diagnostics","volume":"34","author":"Sikkema-Raddatz","year":"2013","journal-title":"Hum. Mutat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.20150002","article-title":"DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing cyclin D3","volume":"212","author":"Thompson","year":"2015","journal-title":"J. Exp. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/gim.2017.1","article-title":"A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology","volume":"19","author":"Vissers","year":"2017","journal-title":"Genet. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2926555","DOI":"10.1155\/2024\/2926555","article-title":"Discovery of a novel DYRK1A mutation (C.524del) in intellectual development disorder autosomal dominant 7 (MRD7): a comprehensive case analysis","volume":"2024","author":"Whitaker","year":"2024","journal-title":"Case Rep. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/gim.2017.246","article-title":"Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders","volume":"20","author":"Wright","year":"2018","journal-title":"Genet. Med."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1813300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:10:19Z","timestamp":1779401419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1813300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":43,"alternative-id":["10.3389\/fgene.2026.1813300"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1813300","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1813300"}}